Skip to content

Evaluation of HbA1c Levels and Ovarian Reserve and Type 1 Diabetes

Evaluation of HbA1c Levels and Ovarian Reserve in Patients With Type 1 Diabetes Diagnosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03907618
Enrollment
104
Registered
2019-04-09
Start date
2018-07-01
Completion date
2019-01-01
Last updated
2019-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Ovarian Failure

Keywords

Antral follicle count, Anti müllerian hormone, Ovarian reserve, HbA1c, type 1 diabetes mellitus

Brief summary

The human ovary is the target of an autoimmune attack, usually in organ or non-specific autoimmune disorders. Serum anti-Müllerian hormone (AMH) levels decrease early in menopause and menopause is seen in women with type 1 diabetes mellitus (DM1) at a young age. DM1 is aimed to show DM1 relationship with ovarian reserve based on the assumption that it will have lower AMH levels than controls, secondary to bad glycemic control and autoimmune attack in women.

Detailed description

The study was designed prospectively. Ovarian functions in healthy volunteer women and patients who use DM1 diagnosed between 18-40 years old will be examined. Gonadotropin and AMH levels will be measured in follicular phase. To calculate the number of antral follicles (AFC) and ovarian volume, ultrasound will be looked at. Fasting and satiety blood glucose, HbA1c and C-peptide levels will be evaluated.

Interventions

DIAGNOSTIC_TESTovarian reserve

To assess ovarian reserve in patients with Type 1 Diabetes Mellitus aged 18-40 years; ultrasonographic and laboratory parameters will be looked at.

Sponsors

Kanuni Sultan Suleyman Training and Research Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* female patients between 18 and 40 years of age who had consent and had gynecological examination in our polyclinic; * study group for patients with type 1 diabetes mellitus healthy volunteers control group

Exclusion criteria

* Other endocrine and / or autoimmune disorders, polycystic ovary syndrome (PCOS) and * previous surgery, which may reduce ovarian reserves; * medical and / or radiotherapy

Design outcomes

Primary

MeasureTime frameDescription
Antral follicle count (AFC)On the 3rd day of the menstrual cycleAFC was calculated by counting 2-10 mm diameter follicles in both ovaries with a standard systematic approach.Recorded as a number.
Anti müllerian hormone (AMH)On the 3rd day of the menstrual cycleAMH concentrations were measured by an enzymatically enhanced bilaterally immunoassay. AMH (pmol / l) saved as.
HbA1cOn the 3rd day of the menstrual cycleHBA1C concentrations were measured by taking venous blood samples in the early morning hours. HBA1C (mmol / mol) saved as.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026